New heart drug tested in first human trial
NCT ID NCT03626662
Summary
This was the first human study of an experimental drug called AMG 890 (now called olpasiran) designed to lower lipoprotein(a), a substance in blood linked to heart disease risk. Researchers tested single doses in about 80 adults with elevated lipoprotein(a) levels to check safety, how the body processes the drug, and whether it reduces lipoprotein(a). This early-phase trial focused on establishing basic safety and biological effects before larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Medical and Analytical eXellence CMAX
Adelaide, South Australia, 5000, Australia
-
Excel Medical Clinical Trials
Boca Raton, Florida, 33434, United States
-
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
-
Linear Clinical Research Limited
Nedlands, Western Australia, 6009, Australia
-
Medpace Inc
Cincinnati, Ohio, 45227, United States
-
New York University
New York, New York, 10016, United States
-
Orange County Research Center
Tustin, California, 92780, United States
-
QPS Miami Research Associates
South Miami, Florida, 33143, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.